L. Pronk

678 total citations
20 papers, 557 citations indexed

About

L. Pronk is a scholar working on Oncology, Dermatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. Pronk has authored 20 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 5 papers in Dermatology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. Pronk's work include Cancer Treatment and Pharmacology (10 papers), Chemotherapy-related skin toxicity (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). L. Pronk is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Chemotherapy-related skin toxicity (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). L. Pronk collaborates with scholars based in Netherlands, United Kingdom and Switzerland. L. Pronk's co-authors include Jaap Verweij, Martin J. van den Bent, André Planting, G. Stoter, Hendrikus G. J. Krouwer, Cees Tijssen, Bernard A. Zonnenberg, J.J. Heimans, C.J.A. Punt and A. Twijnstra and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and British Journal of Cancer.

In The Last Decade

L. Pronk

20 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Pronk Netherlands 10 314 187 178 83 72 20 557
Don W. Shaffer United States 8 407 1.3× 151 0.8× 151 0.8× 138 1.7× 20 0.3× 11 678
C Lavignac France 8 369 1.2× 145 0.8× 249 1.4× 260 3.1× 41 0.6× 14 836
Vittorio Silingardi Italy 12 342 1.1× 99 0.5× 137 0.8× 115 1.4× 106 1.5× 28 619
E. Joosens Belgium 11 258 0.8× 173 0.9× 225 1.3× 133 1.6× 72 1.0× 26 587
Vít Procházka Czechia 16 260 0.8× 69 0.4× 207 1.2× 59 0.7× 48 0.7× 79 584
Shozo Mori Japan 11 288 0.9× 201 1.1× 84 0.5× 138 1.7× 69 1.0× 63 688
H. S. Hochster United States 12 430 1.4× 130 0.7× 62 0.3× 79 1.0× 45 0.6× 21 517
Mohamed Darif United States 12 291 0.9× 153 0.8× 129 0.7× 74 0.9× 23 0.3× 27 791
Jesse G. Dixon United States 9 276 0.9× 104 0.6× 145 0.8× 68 0.8× 77 1.1× 22 502
Marolleau Jp France 7 487 1.6× 80 0.4× 290 1.6× 256 3.1× 42 0.6× 11 919

Countries citing papers authored by L. Pronk

Since Specialization
Citations

This map shows the geographic impact of L. Pronk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Pronk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Pronk more than expected).

Fields of papers citing papers by L. Pronk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Pronk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Pronk. The network helps show where L. Pronk may publish in the future.

Co-authorship network of co-authors of L. Pronk

This figure shows the co-authorship network connecting the top 25 collaborators of L. Pronk. A scholar is included among the top collaborators of L. Pronk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Pronk. L. Pronk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pronk, L., et al.. (2024). A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors. ESMO Open. 9(11). 103730–103730. 4 indexed citations
2.
Attard, Gerhardt, Jos Kitzen, Sarah P. Blagden, et al.. (2007). A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. British Journal of Cancer. 97(10). 1338–1343. 52 indexed citations
3.
Velde, Anje A. te, L. Pronk, Satish Keshav, et al.. (2007). Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohnʼs disease. Inflammatory Bowel Diseases. 13. 647–647. 2 indexed citations
4.
Attard, Gerhardt, Jos Kitzen, Johann S. de Bono, et al.. (2005). A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3166–3166. 7 indexed citations
5.
Aranda, Enrique, Alfredo Carrato, Andrés Cervantes, et al.. (2004). Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer. Annals of Oncology. 15(4). 559–567. 6 indexed citations
6.
Valle, Juan W., Clara Montagut, L. Pronk, et al.. (2004). 287 A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and capecitabine (C) in patients with advanced solid tumors. European Journal of Cancer Supplements. 2(8). 88–88. 1 indexed citations
7.
Schrijvers, D., L. Pronk, Martin Highley, et al.. (2000). Pharmacokinetics of Ifosfamide Are Changed by Combination With Docetaxel. American Journal of Clinical Oncology. 23(4). 358–363. 17 indexed citations
8.
Pronk, L., P. Vasey, Alex Sparreboom, et al.. (2000). A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. British Journal of Cancer. 83(1). 22–29. 88 indexed citations
9.
Verweij, Jaap, J. H. M. Schellens, Jos H. Beijnen, et al.. (2000). Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands. Anti-Cancer Drugs. 11(4). 249–255. 8 indexed citations
10.
Bent, Martin J. van den, et al.. (1999). Phase II Study of Weekly Dose-intensified Cisplatin Chemotherapy with Oral Etoposide in Recurrent Glioma. Journal of Neuro-Oncology. 44(1). 59–64. 9 indexed citations
11.
Pronk, L., Wim L.J. van Putten, V van Beurden, et al.. (1999). The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study. Cancer Chemotherapy and Pharmacology. 43(2). 173–177. 4 indexed citations
12.
Pronk, L., et al.. (1998). Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. British Journal of Cancer. 77(1). 153–158. 18 indexed citations
13.
Pronk, L., et al.. (1998). Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anti-Cancer Drugs. 9(9). 759–764. 16 indexed citations
14.
Pronk, L., D. Schrijvers, Jan H.M. Schellens, et al.. (1998). Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.. PubMed. 25(1 Suppl 2). 23–8. 3 indexed citations
15.
Bent, Martin J. van den, J.J. Heimans, L. Pronk, et al.. (1998). Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology. 51(4). 1140–1145. 156 indexed citations
16.
Pronk, L., et al.. (1997). Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. British Journal of Cancer. 75(3). 417–422. 57 indexed citations
17.
Vasey, P., L. Pronk, Chris Twelves, et al.. (1997). Phase I and pharmacokinetic study of XelodaTM (capecitabine) in combination with docetaxel. European Journal of Cancer. 33. S246–S246. 3 indexed citations
18.
Pronk, L., Jan H.M. Schellens, A.S.T. Planting, et al.. (1997). Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 15(3). 1071–1079. 61 indexed citations
19.
Pronk, L., André Planting, R. Oosterom, et al.. (1994). Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. European Journal of Cancer. 30(7). 1019–1022. 27 indexed citations
20.
Pronk, L. & A. J. G. Swaak. (1991). Pulmonary hypertension in connective tissue disease. Rheumatology International. 11(2). 83–86. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Don W. Shaffer Breakdown of academic impact, for papers by C Lavignac Breakdown of academic impact, for papers by Vittorio Silingardi Breakdown of academic impact, for papers by E. Joosens Breakdown of academic impact, for papers by Vít Procházka Breakdown of academic impact, for papers by Shozo Mori Breakdown of academic impact, for papers by H. S. Hochster Breakdown of academic impact, for papers by Mohamed Darif Breakdown of academic impact, for papers by Jesse G. Dixon Breakdown of academic impact, for papers by Marolleau Jp
Rankless by CCL
2026